Black men with advanced prostate cancer have a greater chance of survival after immunotherapy treatment, at least in part, because of ancestral gene variants in immune responses.

Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, October 16, 2024, 13:00 Hrs [IST] ...

In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen ...

As part of the CURE® Educated Patient® Prostate Cancer Summit, an expert discussed the role genetic testing plays in ...

DelveInsight's 'Metastatic Castration-Sensitive Prostate Cancer Pipeline Insight 2024' report provides comprehensive global ...

Bayer is seeking EMA approval for darolutamide in metastatic hormone-sensitive prostate cancer, building on promising Phase ...

In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients ...

Bayer announced the submission of an application to the European Medicines Agency for the oral androgen receptor inhibitor ...

Up to 20% of patients will develop metastatic castration-resistant disease within five to seven years of diagnosis ...

ORION CORPORATION INVESTOR NEWS 14 OCTOBER 2024 at 11.00 EEST Orion's collaboration partner Bayer submits application for third indication of darolutamide in the EU Orion's collaboration ...

In the trial, a TALZENNA plus XTANDI combination regimen offered overall survival (OS) improvement in metastatic ...

Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...